
Opinion|Videos|February 10, 2025
Shared Decision-Making in Tardive Dyskinesia
Panelists discuss how TD treatment can be optimized through individualized approaches that consider patient-specific factors like symptom severity, comorbidities, concurrent medications, and daily routines, utilizing tools like titration kits to carefully adjust VMAT2 inhibitor dosing while monitoring response and tolerability to achieve the best possible outcomes for each patient.
Advertisement
Episodes in this series

Video series above is prompted by the following:
- How can treatment strategies for TD be individualized (eg, titration kits) based on patient-specific factors?
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Zilganersen Injection, First Drug for Alexander Disease
2
New CKD Outcome Set Tells Pharmacists What to Measure
3
AAP Issue 2026-2027 Guidance on RSV and COVID-19 Immunization
4
Fast-Acting Meloxicam Demonstrates Postoperative Pain Relief and Opioid-Sparing Potential
5
































































































